Published in BMJ on January 13, 1990
The cyclotron saga continues. BMJ (1989) 2.34
Mixed neutron/photon irradiation of unresectable squamous cell carcinomas of the head and neck: the final report of a randomized cooperative trial. Int J Radiat Oncol Biol Phys (1989) 1.08
Cancer survival in Britain is poorer than that of her comparable European neighbours. BMJ (1999) 4.39
New guidelines for urgent referral of patients with cancer are waste of energy. BMJ (2000) 2.66
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Gene therapy for cancer. Lancet (1992) 1.81
c-myc oncogene expression in colorectal cancer. Cancer (1987) 1.60
Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer (1986) 1.47
Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med (1978) 1.44
Detection of the c-myc oncogene product in testicular cancer. Br J Cancer (1985) 1.40
A new marker for testicular cancer. Br J Cancer (1985) 1.39
Centralize cancer services. Br J Hosp Med (1990) 1.38
Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) (1983) 1.37
Does interferon cure cancer? Br Med J (1980) 1.34
Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res (1992) 1.33
Stimulation of lymphocytes from patients with coeliac disease by a subfraction of gluten. Lancet (1976) 1.31
The increasing incidence of testicular cancer in East Anglia. Br J Cancer (1984) 1.28
Human hybridomas from malignant gliomas. Lancet (1982) 1.27
Second opinions for patients with cancer. BMJ (1995) 1.23
A simultaneous flow cytometric assay for c-myc oncoprotein and DNA in nuclei from paraffin embedded material. J Immunol Methods (1985) 1.21
Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol (1999) 1.13
A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes (1987) 1.11
Interventional genetics and cancer treatment. BMJ (1993) 1.10
Human monoclonal antibodies to lung-cancer antigens. Br J Cancer (1981) 1.10
Oncogenes. Lancet (1983) 1.09
c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer (1989) 1.06
Partial purification of tumour-specific transplantation antigens from methylcholanthrene-induced murine sarcomas by immobilized lectins. Br J Cancer (1979) 1.06
The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer (1990) 1.05
Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther (1994) 1.04
The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer (1986) 1.01
Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice. Nature (1978) 1.00
Value of follow up in testicular cancer. Br Med J (Clin Res Ed) (1984) 1.00
The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice. Immunology (1981) 1.00
Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol (1989) 0.99
Monoclonal immunoglobulin rescue from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. Blood (1979) 0.98
Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody. Br J Cancer (1983) 0.98
Tumour inoculation during laparoscopy. Lancet (1993) 0.98
Conventional and complementary treatment for cancer. BMJ (1989) 0.97
Mouse-human hybridomas. The conversion of non-secreting human B cells into Ig secretors. Curr Top Microbiol Immunol (1978) 0.95
Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol (1985) 0.93
Recombinant interferon in advanced breast cancer. Br J Cancer (1984) 0.91
Interferon and cancer. Br Med J (Clin Res Ed) (1983) 0.90
The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand. Immunology (1981) 0.90
Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood (1981) 0.89
Human hybridomas from patients with malignant disease. Br J Cancer (1983) 0.88
Specialist surgeons and survival in breast cancer. Breast cancer is a medical, not a surgical, disease. BMJ (1996) 0.88
Gastric cancer and cimetidine: does delay in diagnosis matter? Lancet (1981) 0.87
Oncoprotein stability after tumour resection. Br J Cancer (1990) 0.87
Testicular cancer and social class in East Anglia. Br J Cancer (1984) 0.87
Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody. J Hepatol (1986) 0.87
Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product. Br J Cancer (1986) 0.85
Monoclonal antibodies in oncology. J Clin Pathol (1982) 0.84
RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1. Exp Clin Endocrinol Diabetes (2011) 0.84
Tumour imaging and drug targeting. Br Med Bull (1984) 0.84
Bleomycin lung: computed tomographic observations. Br J Radiol (1985) 0.84
Oncogenes and germ cell tumours. Int J Androl (1987) 0.83
CAG repeat polymorphism in the DNA polymerase gamma gene in a Polish population: an association with testicular cancer risk. Ann Oncol (2005) 0.83
A global strategy for radiotherapy: a WHO consultation. Clin Oncol (R Coll Radiol) (1999) 0.83
Human monoclonal antibodies. Nature (1982) 0.82
Cancer follow up: time for review. J R Coll Gen Pract (1985) 0.82
Flow cytometric quantitation of the c-myc oncoprotein in archival neoplastic biopsies of the colon. Mol Cell Probes (1987) 0.82
Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. AJNR Am J Neuroradiol (1996) 0.81
Tumour localisation by human monoclonal antibodies. Med Oncol Tumor Pharmacother (1985) 0.81
Overcoming challenges of cancer treatment programmes in developing countries: a sustainable breast cancer initiative in Ethiopia. Clin Oncol (R Coll Radiol) (2008) 0.81
Multidrug resistance and behavioural phenotype of cancer cells. Cell Biol Int (1993) 0.80
Human monoclonal antibodies to glioma cells. Br J Cancer (1981) 0.80
Localisation of malignant glioma by a radiolabelled human monoclonal antibody. J Neurol Neurosurg Psychiatry (1983) 0.80
Immunoprotection by embryonal carcinoma cells for methylcholanthrene-induced murine sarcomas. Nature (1977) 0.80
New combination chemotherapy programme for bladder cancer. Br J Urol (1989) 0.80
Complementary and conventional cancer care: the integration of two cultures. Clin Oncol (R Coll Radiol) (1993) 0.80
c-myc oncogene expression and clinical outcome in carcinoma of the cervix. Mol Cell Probes (1989) 0.80
Expression of c-myc oncogene in coeliac disease. J Clin Pathol (1987) 0.79
The current management of testicular cancer. Br J Urol (1987) 0.79
Cell-surface oligosaccharides expressed by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer. Biochem Soc Trans (1990) 0.79
Primary non-Hodgkin's lymphoma of the liver. Eur J Surg Oncol (1987) 0.79
Suppression of foreign body granuloma by recombinant interferon. Br Med J (Clin Res Ed) (1984) 0.79
Thymic expression of mutated B16:A preproinsulin messenger RNA does not reverse acceleration of NOD diabetes associated with insulin 2 (thymic expressed insulin) knockout. J Autoimmun (2005) 0.78
Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines. Int J Cancer (1994) 0.78
Detection of lymphocytes in malignant gliomas by monoclonal antibodies. J Neurol Neurosurg Psychiatry (1983) 0.78
C-myc expression in cervical cancer. Lancet (1987) 0.78
Cancer genes in gastrointestinal malignancy. Baillieres Clin Gastroenterol (1990) 0.78
Abdominal pain as a presenting symptom of male germ cell tumour. Br J Urol (1985) 0.78
Human genetic therapy. Mol Aspects Med (1993) 0.78
Inhibition of lymphoma hybrids by human interferon. Lancet (1980) 0.78
Combined choriocarcinoma and yolk sac tumor arising in Barrett's esophagus. Cancer (1994) 0.77
Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors. Oncogene (2000) 0.77
Genetic approaches to cancer therapy. Gene Ther (1994) 0.77
New therapeutic modalities for cancer. Acta Oncol (1991) 0.77
Inactivation of the retinoblastoma gene does not lead to loss of TGF-beta receptors or response to TGF-beta in breast cancer cell lines. Oncogene (1991) 0.77
Biological approaches to cancer therapy. J Int Med Res (1989) 0.77
Genetic prodrug activation therapy. Mol Med Today (1997) 0.77
Localisation of glioma by human monoclonal antibody. Lancet (1982) 0.77
[Ventricular topography of the diencephalic ependyma in Rattus rattus (L.)--a scanning electron microscopy study]. J Hirnforsch (1977) 0.77
Generation of a monoclonal antibody to P-glycoprotein peptides using tuberculin-PPD as a carrier. Virchows Arch (1998) 0.76
Gene therapy for cancer. Eur J Cancer (1991) 0.76
The potential of oncogene products as tumour markers. Cancer Surv (1987) 0.76
Computed tomography of testicular tumours: distribution of abdominal lymphadenopathy. Clin Radiol (1986) 0.76
The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol (1990) 0.76
Scanning and transmission electron microscopy of intraventricular dendrite terminals of hypothalamic cerebrospinal fluid contacting neurons in Triturus vulgaris. Z Mikrosk Anat Forsch (1979) 0.76
Genetic prodrug activation therapy. Lancet (1998) 0.76
Serum levels of c-myc and c-ras oncogene products in normal subjects and in patients with neoplastic and non neoplastic conditions. Int J Biol Markers (1988) 0.76
A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung. Br J Cancer (1985) 0.75